LY-2183240

LY-2183240 is a drug that was developed by Eli Lilly and is known for its ability to inhibit the enzyme fatty acid amide hydrolase (FAAH). This enzyme is responsible for breaking down certain types of fatty acids in the body, including anandamide, which is a naturally occurring cannabinoid.

Pharmacology[edit | edit source]

LY-2183240 is a potent and selective inhibitor of FAAH, which means it can increase the levels of anandamide in the body. Anandamide is a neurotransmitter that is involved in pain, depression, appetite, memory, and fertility. By inhibiting FAAH, LY-2183240 can potentially have therapeutic effects in these areas.

Clinical Trials[edit | edit source]

LY-2183240 has been tested in clinical trials for its potential use in treating anxiety disorders and pain. However, the results of these trials have not been published, and it is not currently approved for use in any country.

Side Effects[edit | edit source]

As with any drug, LY-2183240 has potential side effects. These can include nausea, vomiting, dizziness, and fatigue. However, these side effects are generally mild and go away on their own.

See Also[edit | edit source]

LY-2183240 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.